CorrespondenceDenosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis☆
Section snippets
Declaration of competing interest
None.
References (2)
- et al.
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta-analysis
Bone
(2020) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]: 16.9.5 validity of methods of meta-analysis for rare events
Cited by (3)
Advances in osteoporotic bone tissue engineering
2021, Journal of Clinical Medicine
- ☆
Investigation performed at the Department of Orthopaedic Surgery, Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- 1
These authors contributed equally to this work.
© 2020 Elsevier Inc. All rights reserved.